Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Protocol
  • Published:

The cellular thermal shift assay for evaluating drug target interactions in cells


Thermal shift assays are used to study thermal stabilization of proteins upon ligand binding. Such assays have been used extensively on purified proteins in the drug discovery industry and in academia to detect interactions. Recently, we published a proof-of-principle study describing the implementation of thermal shift assays in a cellular format, which we call the cellular thermal shift assay (CETSA). The method allows studies of target engagement of drug candidates in a cellular context, herein exemplified with experimental data on the human kinases p38α and ERK1/2. The assay involves treatment of cells with a compound of interest, heating to denature and precipitate proteins, cell lysis, and the separation of cell debris and aggregates from the soluble protein fraction. Whereas unbound proteins denature and precipitate at elevated temperatures, ligand-bound proteins remain in solution. We describe two procedures for detecting the stabilized protein in the soluble fraction of the samples. One approach involves sample workup and detection using quantitative western blotting, whereas the second is performed directly in solution and relies on the induced proximity of two target-directed antibodies upon binding to soluble protein. The latter protocol has been optimized to allow an increased throughput, as potential applications require large numbers of samples. Both approaches can be completed in a day.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Schematic illustration of CETSA melt curve and ITDRFCETSA procedures using samples of different origins.
Figure 2: The screen format assay procedure.
Figure 3: Illustration of the remaining amount of p38α accessible for detection as a function of the temperature used for heat treatment of HL-60 cells.
Figure 4: Illustration of the amount of stabilized soluble p38α accessible for detection in the presence of increasing concentrations of compounds in HL-60 cells.
Figure 5: Scatterplot of the screening data after conversion to fold signal increase compared with the DMSO-only controls on each plate.

Similar content being viewed by others


  1. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84–87 (2013).

    Article  Google Scholar 

  2. Brandts, J.F. & Lin, L.N. Study of strong to ultratight protein interactions using differential scanning calorimetry. Biochemistry 29, 6927–6940 (1990).

    Article  CAS  Google Scholar 

  3. Crothers, D.M. Statistical thermodynamics of nucleic acid melting transitions with coupled binding equilibria. Biopolymers 10, 2147–2160 (1971).

    Article  CAS  Google Scholar 

  4. Schellman, J.A. Macromolecular binding. Biopolymers 14, 999–1018 (1975).

    Article  CAS  Google Scholar 

  5. Matulis, D., Kranz, J.K., Salemme, F.R. & Todd, M.J. Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 44, 5258–5266 (2005).

    Article  CAS  Google Scholar 

  6. Ericsson, U.B., Hallberg, B.M., Detitta, G.T., Dekker, N. & Nordlund, P. ThermoFluor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem. 357, 289–298 (2006).

    Article  CAS  Google Scholar 

  7. Niesen, F.H., Berglund, H. & Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212–2221 (2007).

    Article  CAS  Google Scholar 

  8. Pantoliano, M.W. et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen. 6, 429–440 (2001).

    Article  CAS  Google Scholar 

  9. Senisterra, G.A. et al. Screening for ligands using a generic and high-throughput light-scattering-based assay. J. Biomol. Screen. 11, 940–948 (2006).

    Article  CAS  Google Scholar 

  10. Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104, 20523–20528 (2007).

    Article  CAS  Google Scholar 

  11. Vedadi, M. et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl. Acad. Sci. USA 103, 15835–15840 (2006).

    Article  CAS  Google Scholar 

  12. Garnett, M.J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012).

    Article  CAS  Google Scholar 

  13. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).

    Article  CAS  Google Scholar 

  14. Feng, B.Y. & Shoichet, B.K. A detergent-based assay for the detection of promiscuous inhibitors. Nat. Protoc. 1, 550–553 (2006).

    Article  CAS  Google Scholar 

  15. Walters, W.P. & Namchuk, M. Designing screens: how to make your hits a hit. Nat. Rev. Drug Disc. 2, 259–266 (2003).

    Article  CAS  Google Scholar 

  16. Nordlund, P. Methods for determining ligand binding to a target protein using a thermal shift assay. UK patent no. GB2490404 (2012).

  17. Weibrecht, I. et al. Proximity ligation assays: a recent addition to the proteomics toolbox. Exp. Rev. Proteom. 7, 401–409 (2010).

    Article  CAS  Google Scholar 

  18. Knaust, R.K. & Nordlund, P. Screening for soluble expression of recombinant proteins in a 96-well format. Anal. Biochem. 297, 79–85 (2001).

    Article  CAS  Google Scholar 

  19. Asial, I. et al. Engineering protein thermostability using a generic activity-independent biophysical screen inside the cell. Nat. Commun. 4, 2901 (2013).

    Article  Google Scholar 

  20. Branca, R.M et al. HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat. Methods 11, 59–62 (2014).

    Article  CAS  Google Scholar 

  21. Eglen, R.M. et al. The use of AlphaScreen technology in HTS: current status. Curr. Chem. Genomics 1, 2–10 (2008).

    Article  CAS  Google Scholar 

  22. Bazin, H., Preaudat, M., Trinquet, E. & Mathis, G. Homogeneous time resolved fluorescence resonance energy transfer using rare earth cryptates as a tool for probing molecular interactions in biology. Spectrochim. Acta. A Mol. Biomol. Spectrosc. 57, 2197–2211 (2001).

    Article  CAS  Google Scholar 

  23. Osmond, R.I.W., Das, S. & Crouch, M.F. Development of cell-based assays for cytokine receptor signaling, using an AlphaScreen SureFire assay format. Anal. Biochem. 403, 94–9101 (2010).

    Article  CAS  Google Scholar 

  24. Bembenek, M.E. et al. Determination of complementary antibody pairs using protein A capture with the AlphaScreen assay format. Anal. Biochem. 408, 321–327 (2011).

    Article  CAS  Google Scholar 

  25. Copeland, R.A., Pompliano, D.L. & Meek, T.D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Disc. 5, 730–739 (2006).

    Article  CAS  Google Scholar 

  26. Lepock, J.R. et al. Influence of transition rates and scan rate on kinetic simulations of differential scanning calorimetry profiles of reversible and irreversible protein denaturation. Biochemistry 31, 12706–12712 (1992).

    Article  CAS  Google Scholar 

  27. Quistgaard, E.M. et al. Structural and biophysical characterization of the cytoplasmic domains of human BAP29 and BAP31. PLoS ONE 8, e71111 (2013).

    Article  CAS  Google Scholar 

  28. Saklatvala, J. et al. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J. Biol. Chem. 271, 6586–6589 (1996).

    Article  CAS  Google Scholar 

  29. Dominguez, C., Powers, D.A. & Tamayo, N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Disc. Dev. 8, 421–430 (2005).

    CAS  Google Scholar 

  30. Aronov, A.M. et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J. Med. Chem. 52, 6362–6368 (2009).

    Article  CAS  Google Scholar 

  31. Zhang, J.H., Chung, T.D. & Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J. Biomol. Screen. 4, 67–73 (1999).

    Article  CAS  Google Scholar 

  32. Richman, D.D., Cleveland, P.H., Oxman, M.N. & Johnson, K.M. The binding of staphylococcal protein A by the sera of different animal species. J. Immunol. 128, 2300–2305 (1982).

    CAS  PubMed  Google Scholar 

Download references


D.M.M., R.J., M.I. and P.N. acknowledge Karolinska Institutet (Distinguished Professor Award), the Swedish Research Council (Vetenskapsrådet) and the Swedish Cancer Society (Cancerfonden). T.L., H. Almqvist and H. Axelsson acknowledge Karolinska Institutet and the Swedish Research Council, which funds Chemical Biology Consortium Sweden, a national infrastructure for research in the field of chemical Biology, as well as Biovitrum for a generous donation of instruments and compound libraries when Chemical Biology Consortium Sweden was inaugurated. We are also grateful to C. Zaniol at PerkinElmer for great support in the development of the AlphaScreen assays.

Author information

Authors and Affiliations



R.J., H. Axelsson, H. Almqvist, M.I., T.L., P.N. and D.M.M. conceived the study; R.J., H. Axelsson, H. Almqvist, T.L. and D.M.M. designed the experiments and the high-throughput formatting of the CETSA procedure; western blot and the AlphaScreen experiments were conducted by R.J., D.M.M., H. Axelsson, H. Almqvist and T.L.; and the manuscript was prepared by R.J., H. Axelsson, H. Almqvist, M.I., T.L., P.N. and D.M.M.

Corresponding authors

Correspondence to Thomas Lundbäck, Pär Nordlund or Daniel Martinez Molina.

Ethics declarations

Competing interests

D.M.M. and P.N. are the founders of Pelago Bioscience AB. The remaining authors declare no competing financial interests.

Integrated supplementary information

Supplementary Figure 1 Cellular integrity after heating.

In order to evaluate the integrity of the cell membrane of HL-60 cells during heating a trypan blue dye exclusion experiment was performed. Aliquots of approximately 3.0x104 HL-60 cells in culture medium were heated to 37, 50, 60, 65 and 70°C respectively for 3 min in the presence of 0.2% (w/v) trypan blue dye and allowed to cool to room temperature for 3 minutes. A 10μl aliquot of the heated cell suspension was subsequently analyzed using a TC20™ automated cell counter. Cells with the ability to exclude trypan blue were considered as retaining their cell membrane integrity whereas dye stained cells were identified as cells with disrupted cell membranes. The data demonstrated that the cell membrane of the HL-60 cells remain intact during heating at 50°C (the temperature at which the ITDRFCETSA experiments were conducted) since no statistically significant decrease in dye exclusion was observed compared to the initial dye exclusion capability (control) of the HL-60 cells. In addition, the data demonstrated that the HL-60 cell membranes are not disrupted unless temperatures above 60°C are reached. This is in agreement with our previous study where several other cell lines demonstrated loss of cell membrane integrity at temperatures above 60°C1.Data are given as the average ± standard deviation (n ≥ 4).

Supplementary Figure 2 Chemical structures.

The chemical structures of the p38α inhibitors; AMG-548 (A), SB203580 (B) and the dual Erk1/2 inhibitor ERK 11e (C).

Supplementary Figure 3 Negative control compound on p38α.

Western blot image illustrating remaining amounts of p38α in the presence of a dual Erk1/2 inhibitor, ERK 11e, in HL-60 cells as a function of temperature. All experiments were performed at three independent occasions and the experiments loaded and assayed in chorus using Western blot.

Supplementary Figure 4 ITDRFCETSA confirmation of CBK derived hit compounds.

An ITDRFCETSA experiment involving the human kinase p38α was performed to verify intracellular target binding of CBK200177 and CBK107148, both of which were identified in Box 4 (High throughput screening procedure for identification of stabilizers of intracellular p38α). Data are presented as the fold increase in AlphaScreen signal for each concentration of compound compared to DMSO controls. The data demonstrate dose dependent thermal stabilization of p38α for both compounds, thus confirming the results from the “High throughput screening procedure for identification of stabilizers of intracellular p38α”.

Supplementary information

Supplementary Figure 1

Cellular integrity after heating. (PDF 176 kb)

Supplementary Figure 2

Chemical structures. (PDF 224 kb)

Supplementary Figure 3

Negative control compound on p38α. (PDF 233 kb)

Supplementary Figure 4

ITDRFCETSA confirmation of CBK derived hit compounds. (PDF 260 kb)

Supplementary Data

Positive control compound on ERK1/2. (PDF 445 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jafari, R., Almqvist, H., Axelsson, H. et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc 9, 2100–2122 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research